Everolimus
- Generic Name
- Everolimus
- Brand Names
- Afinitor, Votubia, Zortress
- Drug Type
- Small Molecule
- Chemical Formula
- C53H83NO14
- CAS Number
- 159351-69-6
- Unique Ingredient Identifier
- 9HW64Q8G6G
- Background
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
- Indication
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease.
Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.
Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
- Associated Conditions
- Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
- Associated Therapies
- -
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
- Conditions
- Interventions
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02152943
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson in Katy, Houston, Texas, United States
🇺🇸MD Anderson in Sugar Land, Sugar Land, Texas, United States
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 35
- Registration Number
- NCT02143726
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
🇺🇸Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT02138929
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 37
- Registration Number
- NCT02137837
- Locations
- 🇺🇸
St. Patrick Hospital, Missoula, Montana, United States
🇺🇸Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States
🇺🇸Clackamas Radiation Oncology Center, Clackamas, Oregon, United States
Belatacept for Renal Transplant Recipients With Delayed Graft Function
- Conditions
- Interventions
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 8
- Registration Number
- NCT02134288
- Locations
- 🇺🇸
The Ohio State Universtiy Wexner Medical Center, Columbus, Ohio, United States
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
- Conditions
- Interventions
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2018-12-10
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 3
- Registration Number
- NCT02134899
- Locations
- 🇫🇷
Bicêtre Hospital, Le Kremlin-Bicêtre, France
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 38
- Registration Number
- NCT02125084
- Locations
- 🇺🇸
Tennessee Oncology, Chattanooga, Tennessee, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 164
- Registration Number
- NCT02123823
- Locations
- 🇰🇷
National Cancer Center, Goyang, Korea, Republic of
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇦🇹LKH-Univ. Hospital Graz, Graz, Austria
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT02120469
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope Rancho Cucamonga, Rancho Cucamonga, California, United States
🇺🇸South Pasadena Cancer Center, South Pasadena, California, United States
REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 78
- Registration Number
- NCT02115113
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.